PRF Technologies Ltd. Announces FDA Clearance Of IND Application For OcuRing-K Phase II Clinical Trial Apr 30
Less than half of directors are independent Mar 12
PRF Technologies Ltd. Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy Jan 21
New major risk - Share price stability Jan 20
PainReform Ltd. and LayerBio, Inc. Announces Safety Data Supporting the Continued Development of OcuRing-K Drop-less, Sustainable-Release Ocular Drug Delivery Platform for Use in Cataract Surgery Jan 13
PainReform Ltd.'s Deepsolar Launches Smart TDD, A Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market Jan 06
Painreform Ltd. Announces Its Pharmaceutical Division Has Completed an R&D Assessment of Layerbio's Proprietary Drop-Less, Sustained-Release Ocular Drug-Delivery Platform Dec 11
PainReform Ltd. Commences Development for OcuRing™?-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy Dec 03
PainReform Ltd., Annual General Meeting, Dec 30, 2025 Nov 26
PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis Nov 13
New major risk - Share price stability Aug 19
New major risk - Revenue and earnings growth Apr 16
PainReform Ltd. (NasdaqCM:PRFX) completed the acquisition of Business Activities Associated with the DeepSolar Technology of BladeRanger Ltd. Mar 07
New minor risk - Financial data availability Mar 03
PainReform Ltd. (NasdaqCM:PRFX) entered into a business acquisition agreement to acquire Business Activities Associated with the DeepSolar Technology of BladeRanger Ltd for ILS 1.8 million. Feb 19
PainReform Ltd. Provides Further Update on Phase 3 Clinical Trial of PRF-110 Dec 27
Painreform Ltd. Announces CFO Changes Dec 06
PainReform Ltd. Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial Nov 20
PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement Nov 08
PainReform Ltd. has filed a Follow-on Equity Offering in the amount of $1.35 million. Oct 17
PainReform Ltd., Annual General Meeting, Sep 30, 2024 Aug 29
PainReform Ltd. Announces Successful Determination of Optimal Delivery Method for PRF-110 in Bunionectomy Procedures Aug 22
painReform Ltd. Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study Aug 20
New major risk - Financial position Aug 18
PainReform Ltd. Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects Aug 13
PainReform Ltd. Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses Aug 08
PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110 Aug 06
PainReform Ltd. Announces New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature Aug 02
PainReform Ltd. Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and Testing Jul 25
PainReform Ltd. Completes Enrollment in the Second Part of Its Phase 3 Bunionectomy Trial for Prf-110 Jun 26
New major risk - Share price stability Jun 14
PainReform Ltd. has completed a Follow-on Equity Offering in the amount of $7.999045 million. Apr 19
Painreform Ltd. Announces Groundbreaking Results from New Studies Demonstrating the Superior In-Vitro Release Rates of PRF-110 Apr 12
PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy Apr 02
PainReform Ltd. has filed a Follow-on Equity Offering in the amount of $5 million. Mar 02
New major risk - Shareholder dilution Jan 21
Insufficient new directors Oct 01
PainReform Ltd. Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File Sep 13
PainReform Ltd. Announces Selection for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary Sep 08
New major risk - Revenue and earnings growth Jun 11
PainReform Ltd. Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery Jun 08
New major risk - Financial position Jun 08
PainReform Ltd. Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery May 19
PainReform Ltd., Annual General Meeting, Jun 08, 2023 May 05
PainReform Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price Requirement Feb 09
PainReform Ltd., Annual General Meeting, Dec 29, 2022 Nov 26
Price target decreased to US$3.00 Nov 16
PainReform Ltd. Provides Further Update on Manufacturing of PRF-110 Nov 09
PainReform Ltd. Provides PRF-110 Manufacturing Update Oct 06
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification Aug 17
Price target decreased to US$3.00 Apr 27
Forecast to breakeven in 2025 May 22
PainReform Ltd. announced that it has received $5.999992 million in funding Mar 21
Director has left the company Mar 10
PainReform Ltd. announced that it expects to receive $5.999992 million in funding Mar 09
PainReform Ltd. Announces Resignation of Assif Stoffman from Board of Directors Mar 04
New 90-day high: US$5.66 Feb 10
PainReform Ltd. Appoints Rita Keynan as Vice President of Pharmaceutical Operations Jan 08
New 90-day low: US$4.06 Jan 07
PainReform Appoints Ilan Hadar as Chief Executive Officer Nov 24
PainReform Ltd. Welcomes Ellen Baron as A Member of Board of Directors Nov 14
PainReform Ltd. Appoints Augustine Lawlor as Member of Board of Directors Nov 10
PainReform Ltd. has completed an IPO in the amount of $20 million. Sep 02